Studies have shown that vedolizumab is effective as both induction and maintenance therapy in moderately to severely active UC, the disease remission rate is higher than that of TNF antagonists,[42,43] and does not significantly increase the risk of serious systemic opportunistic infections.[44] Additionally, activated PLTs are active coconspirators of inflammation and tissue damage and represent a significant risk factor for the amplification of intestinal inflammation. Here, TNF is linked to Opportunistic infection.